2026 Agenda

Welcome Day

Thursday, 2/26/26

Poster Session & Welcome Reception​

6:00 PM - 8:00 PM

Hall of Fame Rotunda

Sponsored by Johnson & Johnson and Bristol Myers Squibb

Industry attendance for this event is exclusive to only the sponsors of the Poster Session & Welcome Reception

Day One

Friday, 2/27/26

Benign Hematology

Pre-Malignant Hematologic Disorders: What Do Community Providers Need to Know?

1L Standard of Care Across Lymphoid Malignancies: What's New in 2026?

1L Standard of Care Across Myeloid Malignancies: What's New in 2026?

Considerations in Treating Patients with High-Risk Hematologic Malignancies

Challenging Clinical Scenarios in the Community

Breakfast Industry Symposium (Non-CE)

7:20 AM - 8:20 AM

Event Hall

Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 2L+ FL
Speaker: Jonathan Abbas, MD

Sponsored by Genmab and AbbVie

Industry attendance is limited to breakfast industry symposium sponsors only

Welcome & Opening Remarks

8:30 AM - 8:50 AM

CMA Theater

Chairs:
Jesús Berdeja, MD (Greco-Hainsworth Tennessee Oncology Centers for Research)
Andrew Kuykendall, MD (Moffitt Cancer Center)
Joanna Rhodes, MD, MSCE (Rutgers Cancer Institute of New Jersey)

Benign Hematology

Session Chair: Jennifer Green, MD (Tennessee Oncology)

CMA Theater

8:50 AM
Evolving Diagnostics in Iron Deficiency Anemia
Angela Weyand, MD (University of Michigan)

8:58 AM
The Bleeding Patient Consult
Michelle Chi, MD (Vanderbilt Health)

9:06 AM
New Developments in Sickle Cell Disease
Scott Peslak, MD, PhD (University of Pennsylvania)

9:14 AM
TTP/HUS
Spero Cataland, MD (The Ohio State University)

9:22 AM
Update in Venous Thromboembolism
Adam Cuker, MD, M
S (University of Pennsylvania)

9:30 AM
Panel Discussion + Q&A

Pre-Malignant Hematologic Disorders: What Do Community Providers Need to Know?

Session Chair: Michael Byrne, DO, FACP (Greco-Hainsworth Tennessee Oncology Centers for Research)

CMA Theater

9:48 AM
MGUS/ SMM
Caitlin Costello, MD (University of California San Diego)

9:56 AM
CHIP/CCUS
Zhuoer Xie, MD, MS (Moffitt Cancer Center)

10:04 AM
MBL: Implications on Infectious Risk
Erin Mulvey, MD, MSCI (Weill Cornell Medicine)

10:12 AM
Panel Discussion + Q&A

Networking Break

10:30 AM - 11:00 AM

Grand Foyer

1L Standard of Care Across Lymphoid Malignancies: What's New in 2026?

Session Chair: Jason Chandler, MD (West Cancer Center & Research Institute​)

CMA Theater

11:00 AM
Debate: Single Agent Monotherapy vs Fixed Duration Combos in Frontline CLL
Moderator: Matthew Lunning, DO, FACP (University of Nebraska)
Adam Kittai, MD (Mount Sinai Health System)
Callie Coombs, MD (University of California Irvine)

11:20 AM
Multiple Myeloma
Amrita Krishnan, MD, FACP (City of Hope)

11:28 AM
Diffuse Large B-Cell Lymphoma
Ryan Lynch, MD (Fred Hutch Cancer Center)

11:36 AM
Hodgkin’s Lymphoma
Boyu Hu, MD (Huntsman Cancer Institute)

11:44 AM
Indolent Lymphomas
Elizabeth Brém, MD (University of California Irvine)

11:52 AM
Panel Discussion + Q&A

Lunch Industry Symposium (Non-CE)

12:25 PM - 1:25 PM

Event Hall

Reignite the Spark: Clinical Conversations about Jaypirca® (pirtobrutinib)
Speaker: Callie Coombs, MD (University of California Irvine)

Sponsored by Lilly

Industry attendance is limited to lunch industry symposium sponsor only

1L Standard of Care Across Myeloid Malignancies: What's New in 2026?

Session Chair: Ruben Mesa, MD, FACP (Atrium Health Levine Cancer Institute)

CMA Theater

1:40 PM
Myeloproliferative Neoplasms
Gabriela Hobbs, MD (Massachusetts General Hospital)

1:48 PM
Myelofibrosis
John Mascarenhas, MD (Mount Sinai Health System)

1:56 PM
Chronic Myeloid Leukemia
Srinivas Tantravahi, MBBS, MRCP (Huntsman Cancer Institute)

2:04 PM
Myelodysplastic Syndromes
Anthony Hunter, MD (Winship Cancer Institute of Emory University)

2:12 PM
Panel Discussion + Q&A

Considerations in Treating Patients with High-Risk Hematologic Malignancies

Session Chair: Joshua Richter, MD, FACP (Mount Sinai Health System)

CMA Theater

2:32 PM
Defining High-Risk Disease in Lymphoid Malignancies
Jeremy Abramson, MD (Harvard Medical School)

2:40 PM
High-Risk Multiple Myeloma: Time For a Paradigm Change?
Natalie Callander, MD (University of Wisconsin)

2:48 PM
TP53-Mutated AML and MDS
David Sallman, MD (
Moffitt Cancer Center)

2:56 PM
Panel Discussion + Q&A

Networking Break

3:15 PM - 3:45 PM

Grand Foyer

Challenging Clinical Scenarios in the Community

Session Chair: Alexander Perl, MD (University of Pennsylvania)

CMA Theater

3:45 PM
Multiple Myeloma in Patients with Frailty or Comorbidities
Rahul Banerjee, MD, FACP (Fred Hutch Cancer Center)

3:53 PM
How To Tackle Curative Intent in Lymphoma Patients With Cardiac Comorbidities
Sarah Rutherford, MD (Weill Cornell Medicine)

4:01 PM
MDS/MPN Overlap Syndromes
Eric Padron, MD (Moffitt Cancer Center)

4:09 PM
Debate: Intensive vs Less Intensive Induction For The Treatment of Older, But Fit, Patients With Newly Diagnosed AML
Moderator: Matthew Lunning, DO, FACP (University of Nebraska)
Dan Pollyea, MD, MS (University of Colorado School of Medicine)
Jeffrey Lancet, MD (Moffitt Cancer Center)

4:29 PM
Panel Discussion + Q&A

Day Two

Saturday, 2/28/26

Breakfast Industry Symposium (Non-CE)

7:30 AM - 8:20 AM

Event Hall

LYNOZYFIC in The Treatment of 5L+ Relapsed/Refractory Multiple Myeloma
Speaker: Sherif Farag, MD (Community Health Network MD Anderson Cancer Center Stem Cell Transplant & Cellular Therapy Institute)

Sponsored by Regeneron

Industry attendance is limited to breakfast industry symposium sponsor only

MRD Across Hematologic Malignancies

Non-Cellular Approaches in Treating Relapsed/Refractory Hematologic Malignancies

Cellular and T-cell Redirecting Therapies in Hematologic Malignancies

Amuse-Bouche: Myeloma at the Movies

Advancing Community Care

The Evolving Treatment Landscape Across Hematologic Malignancies: What's on the Horizon?

Opening Remarks

8:30 AM - 8:45 AM

CMA Theater

Chairs:
Jesús Berdeja, MD (Greco-Hainsworth Tennessee Oncology Centers for Research)
Andrew Kuykendall, MD (Moffitt Cancer Center)
Joanna Rhodes, MD, MSCE (Rutgers Cancer Institute of New Jersey)

MRD Across Hematologic Malignancies

Session Chair: Christopher Benton, MD (Rocky Mountain Cancer Centers)

CMA Theater

8:45 AM
MRD in AML: Who, What, When, and How?
Rory Shallis, MD (Moffitt Cancer Center)

8:53 AM
Defining The Value of uMRD in CLL
Chaitra Ujjani, MD (Fred Hutch Cancer Center)

9:01 AM
MRD in Multiple Myeloma: How, When and Why?
Noopur Raje, MD (Massachusetts General Hospital)

9:09 AM
ctDNA in Lymphoma
Sairah Ahmed, MD (MD Anderson Cancer Center)

9:17 AM
Debate: Is Monotherapy Maintenance Until Progression The Optimal Approach To Maintenance Therapy in Multiple Myeloma in The Era of Quadruplet Induction?
Moderator: Matthew Lunning, DO, FACP (University of Nebraska)
Peter Voorhees, MD (Atrium Health Levine Cancer Institute)
Faith Davies, MD (NYU Langone Health)

9:37 AM
Panel Discussion + Q&A

Non-Cellular Approaches in Treating Relapsed/Refractory Hematologic Malignancies

Session Chair: Katie Marcucci, DMSc, PA-C, CPAAPA (Tennessee Oncology)

CMA Theater

9:55 AM
Multiple Myeloma
Mansi Shah, MD (Rutgers Cancer Institute of New Jersey)

10:03 AM
CLL
Jacqueline Barrientos, MD, MS (Mount Sinai Health System)

10:11 AM
Indolent Lymphomas
Krish Patel, MD (Sarah Cannon Research Institute)

10:19 AM
Acute Myeloid Leukemia
Rami Komrokji, MD (Moffitt Cancer Center)

10:27 AM
Panel Discussion + Q&A

Networking Break

10:45 AM - 11:15 AM

Grand Foyer

Cellular and T-cell Redirecting Therapies in Hematologic Malignancies

Session Chair: Yi Lin, MD, PhD (Mayo Clinic)

CMA Theater

11:15 AM
CAR-T in Multiple Myeloma
Krina Patel, MD (MD Anderson Cancer Center)

11:23 AM
CAR-T in Non-Hodgkin’s Lymphoma
Elise Chong, MD (University of Pennsylvania)

11:31 AM
Bispecifics in Multiple Myeloma
Susan Bal, MD (University of Alabama Birmingham)

11:39 AM
Bispecifics in Lymphomas
Tycel Phillips, MD (
City of Hope)

11:47 AM
Managing Acute Toxicities with Cellular and T-cell Redirecting Therapies
Babis Andreadis, MD, MS (University of California San Francisco)

11:55 AM
Panel Discussion + Q&A

Lunch Symposium (Non-CE)

12:40 PM - 1:40 PM

Event Hall

Optimal Sequencing in RRMM
Peter Voorhees, MD (Atrium Health Levine Cancer Institute)

Sponsored by Kite and Arcellx and Johnson & Johnson

Industry attendance is limited to lunch symposium sponsors only

Advancing Community Care

Session Chair: Jonathan Abbas, MD (Tennessee Oncology)

CMA Theater

1:55 PM
Utilizing Remote Consultation To Optimize Patient Care in The Community Setting
Jennifer Green, MD (Tennessee Oncology)

2:03 PM
Utilizing Frailty Indexes
Reena Jayani-Kosarzycki, MD, MSCI (Vanderbilt Health)

2:11 PM
Bringing Bispecifics to the Community
Tara Graff, DO, MS (Mission Cancer + Blood)

2:19 PM
Managing Long-Term Toxicities With Cellular and T-cell Redirecting Therapies
Adam Cohen, MD (University of Pennsylvania)

2:27 PM
Panel Discussion +Q&A

Networking Break

2:47 PM - 3:17 PM

Grand Foyer

The Evolving Treatment Landscape Across Hematologic Malignancies: What's On The Horizon?

Session Chair: Vernon Wu, MD (New York Cancer and Blood Specialists)

CMA Theater

3:17 PM
Multiple Myeloma
Ajay Nooka, MD, MPH (Winship Cancer Institute of Emory University)

3:25 PM
CLL
Deborah Stephens, DO (University of North Carolina School of Medicine)

3:33 PM
Non-Hodgkin’s Lymphoma
Sameh Gaballa, MD (Moffitt Cancer Center)

3:41 PM
AML+MDS
Uma Borate, MBBS (The Ohio State University)

3:49 PM
MPNs +SM+CML
Kristen Pettit, MD (University of Michigan)

3:57 PM
Q&A

Keynote Speaker (Non-CE)

David Fajgenbaum, MD, MBA, MSc

Associate Professor of Medicine at the University of Pennsylvania and Co-Founder and President of Everycure

From Chasing My Cure to Every Cure: Utilizing Novel Approaches to Uncover New Uses for Existing Medicines

4:12 PM - 4:55 PM

CMA Theatre

Farewell Reception

5:00 PM - 6:00 PM

Grand Foyer

*Agenda is subject to change.

Experience Nashville, TN

Come for the education.
Stay for the fun.